ProMIS Neurosciences Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
Canada (Federal Level)
Business Address
SUITE 200, 1920 YONGE STREET, TORONTO, A6, M4S 3E2
Mailing Address
SUITE 200, 1920 YONGE STREET, TORONTO, A6, M4S 3E2
Phone
416-847-6898
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$18.91M
Total Assets
$13.29M
Cash & Equivalents
$2.68
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 25, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | March 25, 2026 | View on SEC |
| 8-K Current report of material events | March 25, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | March 18, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | March 18, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 3 Initial insider ownership report | February 25, 2026 | View on SEC |
| 4 Insider stock transaction report | February 23, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
Annual Reports
10-K
March 25, 2026
- Advancing PMN310, a precision antibody treatment for Alzheimer’s disease currently in Phase 1a clinical trials.
- Potential for high-value partnership or buyout if clinical results demonstrate superior safety profiles.
Insider Trading
STRONG BUY
3 insiders
6 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.